Ocular Therapeutix Growth, Revenue, Number of Employees and Funding


Boston, MA USA
Total Funding:$187.9M
Lead Investor(s):MidCap Financial, Silicon Valley Bank

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • Ocular Therapeutix's revenue is currently $2M per year.
  • Ocular Therapeutix received $37.5M in venture funding in February 2019.
  • Ocular Therapeutix's revenue per employee is $11307
  • Ocular Therapeutix's total funding is $187.9M.

Employee Data

  • Ocular Therapeutix has 176 Employees.
  • Ocular Therapeutix grew their employee count by 47% last year.
  • Ocular Therapeutix currently has 35 job openings.

What Is Ocular Therapeutix?

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix's lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals


Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Agios Pharmaceu...
Adelphi Values
Boston Biomedic...
Acceleron Pharm...
Orbis Clinical
Long Term Pharm...
Trinity Partner...
Frenova Renal R...

Ocular Therapeutix News

20-Mar-19 - A Director at Ocular Therapeutix (NASDAQ: OCUL) is Buying Shares

Today, a Director at Ocular Therapeutix (OCUL – Research Report), Heier Jeffrey, bought shares of OCUL for $99.6K. This recent transaction

7-Mar-19 - Ocular Therapeutix (OCUL) CEO Antony Mattessich on Q4 2018

Ocular Therapeutix (NASDAQ:OCUL) Q4 2018 Earnings Conference Call March 7, 2019 4:30 PM ET. Company Participants. Antony Mattessich

25-Feb-19 - The Story Around Ocular Therapeutix Brightens

The shares of Ocular Therapeutix jumped 15% in trading Friday as the company entered into a debt facility with favorable terms. This lifted an

Ocular Therapeutix Funding

DateAmountRoundLead InvestorsReference
2013-06-11$UndisclosedUndisclosedBaxter VenturesArticle
2015-06-04$UndisclosedUndisclosedMorgan StanleyArticle
2017-01-25$25.0MUndisclosedCantor Fitzgerald & CoArticle
2018-01-26$37.3MUndisclosedPiper Jaffray & CoArticle
2019-01-02$25.0MUndisclosedMidCap FinancialArticle

Ocular Therapeutix Executive Hires

2016-01-12Jonathan H. TalamoChief Medical OfficerArticle
2016-10-21Andy HurleyChief Commercial OfficerArticle
2017-04-07George MigauskyInterim Chief Financial OfficerArticle
2017-08-02Antony MattessichCEOArticle
2017-08-04Daniel BollagSVP Regulatory Affairs, Pharmacovigilance/QualityArticle
2017-09-11Michael GoldsteinCMOArticle
2017-09-26Donald NotmanChief Financial OfficerArticle
2018-01-09Kevin HanleySVP Technical OperationsArticle
2018-12-07Chad BrinesVice President, SalesArticle

Ocular Therapeutix Staff Cuts

DateNumber of EmployeesLocationReference